Discriminant analysis and machine learning approach for evaluating and improving the performance of immunohistochemical algorithms for COO classification of DLBCL

@laura_korin Indeed. Read this from our group (Mexican group) https://t.co/AmnFhN8Vvy

RT @hematologo: Here, the references. If we start with FOXP1 and GCET1 we would get no-GC/ABC identify. Then we could try personalized the…

Here, the references. If we start with FOXP1 and GCET1 we would get no-GC/ABC identify. Then we could try personalized the treatment, where GC can try to be salvage with DHAP + ASCT and non-GC polatuzumab plus chemo (i.e. ICE) + ASCT. https://t.co/AmnFhN8

@DavidSteensma @KentsisResearch @WHO Your right @DavidSteensma, however In our experience we need to get better IHQ. For example, we reported a study where using machine learning the accuracy is really good and Hans was not the best. https://t.co/AmnFhMQMh